Rationale: Obstructive sleep apnea (OSA) is a risk factor for cardiovascular death in middle-aged subjects, but it is not known whether it is also a risk factor in the elderly.
Objectives: To investigate whether OSA is a risk factor for cardiovascular death and to assess whether continuous positive airway pressure (CPAP) treatment is associated with a change in risk in the elderly.
Methods: Prospective, observational study of a consecutive cohort of elderly patients (≥65 yr) studied for suspicion of OSA between 1998 and 2007. Patients with an apnea–hypopnea index (AHI) less than 15 were the control group. OSA was defined as mild to moderate (AHI, 15–29) or severe (AHI, ≥30). Patients with OSA were classified as CPAP-treated (adherence ≥ 4 h/d) or untreated (adherence < 4 h/d or not prescribed). Participants were monitored until December 2009. The end point was cardiovascular death. A multivariate Cox survival analysis was used to determine the independent impact of OSA and CPAP treatment on cardiovascular mortality.
Measurements and Main Results: A total of 939 elderly were studied (median follow-up, 69 mo). Compared with the control group, the fully adjusted hazard ratios for cardiovascular mortality were 2.25 (confidence interval [CI], 1.41 to 3.61) for the untreated severe OSA group, 0.93 (CI, 0.46 to 1.89) for the CPAP-treated group, and 1.38 (CI, 0.73 to 2.64) for the untreated mild to moderate OSA group.
Conclusions: Severe OSA not treated with CPAP is associated with cardiovascular death in the elderly, and adequate CPAP treatment may reduce this risk.
In middle-aged subjects, obstructive sleep apnea is a risk factor for cardiovascular death and continuous positive airway pressure (CPAP) treatment seems to significantly reduce this risk. However, it is not known whether obstructive sleep apnea is a risk factor for the elderly, or what the effect of CPAP on this population might be.
Severe obstructive sleep apnea not treated with CPAP is associated with cardiovascular death in the elderly, and adequate CPAP treatment may reduce this risk.
Nowadays there is little doubt that obstructive sleep apnea (OSA) is a public health problem, on account of both its high prevalence in the general population (1) and its association with increased morbidity and mortality in the short term (traffic and workplace accidents) (2, 3) and the long term (arterial hypertension and cardiovascular events [CVEs]) (4, 5). Continuous positive airway pressure (CPAP) is the most cost-effective treatment for severe or symptomatic forms of OSA (6), and it has demonstrated a positive effect on blood pressure levels (7) and the incidence of fatal and nonfatal CVEs (4, 8–10).
Although we are aware that the prevalence of OSA increases with age (11, 12), few studies have analyzed the impact of OSA or CPAP treatment in a series exclusively comprising elderly people. This is probably because it is difficult to establish a distinction between the physiological and the pathological aspects, and because various comorbidities that act as confounding variables are often present. Despite this lack of scientific evidence, one of four sleep studies is performed on an individual older than 65 years, and CPAP treatment is prescribed in two-thirds of these cases (13).
Some authors have observed an excess of all-cause mortality in patients with severe untreated OSA (14, 15), especially in young people (16–18), whereas elderly individuals could present some compensatory mechanisms that would allow them to resist the action of intermittent hypoxia (19–21). Other authors, however, have observed that the presence of moderate–severe untreated OSA, even at an advanced age, is associated with greater cardio- and cerebrovascular risk (8, 22–27), as well as a higher mortality rate (28, 29), and that CPAP treatment seems to significantly reduce this risk (8, 23). In the light of this controversy, the ageing population and the growing demands of elderly people in our sleep units make it imperative to carry out studies that broaden our scientific evidence on this issue, as their conclusions could be immediately applicable to clinical practice. Therefore, the objective of our study was to analyze the impact of OSA and CPAP treatment on cardiovascular mortality in a large range of individuals of both sexes, all at least 65 years of age, who were referred to sleep units for suspected OSA.
Some of the results of the study have previously been reported in the form of an abstract (30).
We performed a prospective observational study of consecutive patients at least 65 years of age and referred between December 1998 and December 2007 to the sleep units of Requena Hospital (Valencia, Spain) or Valme Hospital (Seville, Spain) for suspected OSA. Exclusion criteria included previous treatment with CPAP, unwillingness to undergo a sleep study, and the presence of a central sleep apnea syndrome (more than 50% of apneic events). The ethics committees of both institutions approved the study.
All the baseline variables were systematically recorded, using a standardized protocol, before the sleep study, with the participants in a stable condition. The following variables were assessed: age, sex, hospital of reference, body mass index (BMI), type of sleep study (polysomnography vs. respiratory polygraphy), previous CVE (stroke, heart failure, arrhythmias, and ischemic heart disease), alcohol intake (grams per day), and dichotomous cardiovascular risk factors: smoking (≥30 pack-years), arterial hypertension (systolic/diastolic blood pressure ≥ 140/90 in two or more outpatient measurements or use of antihypertensive medication), fasting glucose levels higher than 7 mmol/L (125 mg/dl) in two or more measurements or use of antihyperglycemic medication and dyslipidemia (fasting levels of total cholesterol or triglycerides higher than 5.17 mmol/L [>200 mg/dl]), or use of antihyperlipidemic medication. Heart failure was defined via the collection of echocardiographic data or other tests indicated for its conclusive diagnosis, or via the prescription of specific medication; arrhythmias were defined by their detection by ECG or by the patient’s adherence to specific treatment; ischemic heart disease was defined by the results of conclusive tests, myocardial infarction, angina, or previous coronary revascularization, or the prescription of antianginal medication; and, finally, stroke was defined by the presence of confirmative image tests and a compatible clinical picture, as assessed by a neurological specialist. All these tests and treatments were implemented by the corresponding specialists. The OSA-related clinical history and sleep study results were also recorded. Hypersomnia was evaluated on the basis of the validated Spanish version of the Epworth Sleepiness Scale (ESS) (31). Patients with cardiovascular risk factors or previous cardiovascular events received appropriate medical treatment, under the supervision of the corresponding physician.
We followed the Spanish Society of Pneumology and Thoracic Surgery guidelines for diagnosis and treatment of OSA (32, 33). Every participant was subjected to a sleep study, either full standard polysomnography (PSG) (Compumedics PS, Melbourne, Australia) or respiratory polygraphy (RP) with a device previously validated against PSG (Apnoscreen II plus [Erich Jaeger GmbH and Co. KG, Wurzburg, Germany] or Embletta PDS [ResMed, Sydney, Australia]) (34, 35). PSG included continuous recording of electroencephalogram, electro-oculogram, electromyogram, and electrocardiogram; and evaluations of nasal airflow, thoracic and abdominal band movements, and SaO2, according to standard criteria (36). RP included continuous recording of oronasal flow and pressure, heart rate, thoracic and abdominal respiratory movements, and SaO2. A full PSG was performed on all the patients undergoing RP who presented recording artifacts, a discrepancy between the RP result and the pretest clinical probability/suspicion of OSA (especially in patients with a high pretest probability and RP results with no alterations), predominance of central events, or a subjective sleep time of less than 3 hours. All the data were recorded manually by the investigators. Apnea was defined as an interruption of oronasal airflow exceeding 10 seconds, and it was classified as obstructive or central, depending on whether respiratory effort was present or absent. Hypopnea was defined as a 30–90% reduction in the oronasal airflow exceeding 10 seconds and associated with a desaturation of 4% or more (37). The apnea–hypopnea index (AHI) was defined as the number of apneas plus hypopneas per hour of sleep (PSG) or recording (RP). OSA was diagnosed if the AHI was equal to or more than 15, and was classified as mild to moderate (AHI between 15 and 29) or severe (AHI ≥ 30). CPAP treatment was offered to all the patients with an AHI of at least 30, regardless of symptoms, and to those with an AHI between 15 and 29 and OSA symptoms, especially daytime hypersomnia (an ESS > 10) not explained by any other cause. CPAP was titrated in the sleep laboratory on a second night by either full standard PSG or an autotitrating CPAP device. The patients were told to follow their usual lifestyle when undertaking the sleep studies, regarding both their habitual medication and other circumstances.
Adherence to CPAP was always objectively assessed by reading the time counter of the device from the start of treatment to the end of follow-up (death or censorship). Patients were classified as being adequately treated with CPAP if treatment had been started and the average cumulative adherence was at least 4 hours/day, and as untreated if CPAP was not prescribed or if the patient declined to use or could not tolerate the device or was persistently noncompliant (average use, <4 h/d).
The follow-up ended on December 31, 2009. The patients with OSA were reviewed at 3-month intervals during the first year and every 12 months thereafter in the outpatient sleep clinic of one of the two centers, using a standardized protocol. All the data recorded from the outpatient sleep clinic were backed up by reviewing the clinical histories and the hospitals’ computer databases, as well as those of primary care. In case of any doubt or lack of information, an additional medical visit was arranged. A patient was considered lost to follow-up only if the end-point data could not be established at the end of the study.
The study’s main end point, designed before the study started, was cardiovascular death (defined as death from stroke, heart failure, or myocardial infarction). Secondary end points included all-cause mortality and mortality from stroke, heart failure, and myocardial infarction. Vital status at the end of follow-up was thoroughly assessed by using multiple concurrent approaches, including review of hospital and outpatient medical records and computerized databases, and when necessary, by contacting the patient, patient’s relatives, or primary care physician. When a participant died, information about the cause and date of death was obtained from the hospital medical records if the patient died in the hospital, or from official death certificates.
The SPSS 17.0 package (SPSS Inc., Chicago, IL) was used for the analysis. On the basis of the results of the sleep study and CPAP treatment, four groups were defined: control group without OSA (AHI < 15), untreated mild–moderate OSA (AHI 15–29), untreated severe OSA (AHI ≥ 30), and OSA with effective CPAP treatment (at least 4 h/d). Normality in the variable distributions was assessed by Kolmogorov-Smirnov test. Continuous variables are expressed as means (SD) or medians (IQR) and qualitative variables as absolute values and percentages. The baseline differences between the groups were analyzed by one-way analysis of variance with Bonferroni correction or by chi-square test and Fisher exact tests, as appropriate for qualitative variables.
Cumulative cardiovascular mortality for each OSA group was calculated according to the Kaplan-Meier method, and mortality curves were compared by log-rank test. Censoring occurred if CPAP treatment was started (in a subject initially untreated) or if CPAP was withdrawn because of OSA resolution, before the termination of the study. Patients who died of noncardiovascular causes were censored at the time of death. Patients lost to follow-up were excluded from the analysis.
Clinically relevant variables, in the opinion of the researchers, were entered into a Cox proportional hazard model analysis to determine the variables independently associated with mortality in the study groups. The following variables were finally selected to enter in the Cox model: age, BMI, sex, ESS, smoking habit, arterial hypertension, diabetes mellitus, dyslipidemia, respiratory failure, previous CVE, and OSA groups. The results were expressed as hazard ratio (HR) and 95% confidence interval (CI), and a P value less than 0.05 was considered statistically significant. Diagnostic and residual plots were examined for all variables to test the proportional hazards assumptions, and none of them were statistically significant.
Sensitivity analyses were performed to clarify the separate contribution of OSA severity and treatment adherence to cardiovascular death. First, to assess the contribution of CPAP adherence, an additional multivariate Cox regression analysis was performed, including only those patients who began CPAP treatment. In this analysis, CPAP adherence and AHI were assessed as continuous variables instead of the various OSA groups. Second, to analyze the contribution of OSA severity, a new multivariate analysis was performed, including only untreated patients. In this analysis, AHI was assessed as a continuous variable instead of the various OSA groups. Last, a subgroup of patients greater than 75 years of age was also analyzed and the risks of all-cause mortality and specific cardiovascular and noncardiovascular mortality were also compared between the studied OSA groups.
Initially, 1005 elderly patients with suspected OSA were included; 62 were excluded and 4 were lost during the follow-up, leaving 939 individuals. Four groups were established: control group (n = 155), mild–moderate OSA without CPAP (n = 108), severe OSA without CPAP (n = 173), and OSA with CPAP (n = 503) (Figure 1). The baseline characteristics of the study groups are shown in Table 1. Significant differences were observed between the OSA groups in BMI, ESS, percentage of previous CVEs, type of sleep study, and reference clinic. The median follow-up was 69 months (interquartile range, 49 to 87 mo), during which 190 deaths occurred (20.2%); 100 of these (52.6%) were of cardiovascular origin (Table 2). Patients had a mean (SD) CPAP compliance of 6.4 (1.4) hours for the OSA group that used CPAP for at least 4 hours/day and 0.9 (0.9) hours for the intolerant OSA group. Fifty-seven percent of the elderly were studied by means of RP and the remaining 43% by PSG.
|Variable||AHI < 15 Control Group (n = 155)||AHI 15–29 without CPAP (n = 108)||AHI ≥ 30 without CPAP (n = 173)||OSA with CPAP (n = 503)|
|Age, yr||70.9 (4.4)||71.7 (5.2)||71,9 (4.5)||70.1 (4.2)|
|Sex, % males||60%||65.7%||71.7%||62.2%|
|BMI, kg/m2||32.4 (5.1)||33.6 (4.4)||34.8 (6)||35.1 (5.9)|
|ESS||8.4 (4.5)||7.8 (4.2)||11.4 (4.7)||11.6 (4.9)|
|AHI, events/h||6.6 (3.7)||21.3 (4.5)||58.6 (20.9)||52.2 (23.5)|
|Smoked ≥30 pack-years||41%||42%||47%||41%|
|Alcohol intake, g/d||8.3 (14.4)||8,9 (19.2)||7.8 (19.9)||9.4 (22.4)|
|Type of sleep study†||37%||53%||30%||45%|
|Cause of Death||AHI < 15 (n = 155)||AHI 15–29 without CPAP (n = 108)||AHI ≥ 30 without CPAP (n = 173)||OSA with CPAP (n = 503)|
Figure 2 shows Kaplan-Meier curves; it can be seen that cumulative cardiovascular mortality was significantly higher in untreated severe OSA compared with the control group (log-rank test, 11.39; P = 0.001). The mild-to-moderate nontreated OSA group presented a nonsignificant increase in cumulative cardiovascular mortality compared with the control group (log-rank test, 3.13; P = 0.08). Cumulative cardiovascular mortality in the CPAP-treated OSA group was similar to that of the non-OSA group (log-rank test, 0.09; P = 0.77).
Table 3 shows the fully adjusted Cox analysis results. To analyze the impact of the type of sleep study and sleep clinic as potential confounders in the final association between OSA and cardiovascular mortality, these two variables were forced into the multivariate adjusted Cox analysis. The final model did not change with the inclusion of both variables. It can be seen that those patients with severe untreated OSA or poor CPAP adherence presented a greater risk of cardiovascular death (HR, 2.25; 95% CI, 1.41 to 3.61; P = 0.001) compared with the control group. No significant differences in cardiovascular mortality were observed, however, between patients with OSA treated by CPAP, patients with mild–moderate OSA without treatment, and those without OSA.
|Unadjusted||Partially Adjusted*||Fully Adjusted†|
|Variable||HR (95% CI)||P Value||HR (95% CI)||P Value||HR (95% CI)||P Value|
|Age||1.09 (1.05–1.14)||0.0001||1.09 (1.04–1.13)||0.0001||1.06 (1.03–1.11)||0.002|
|Sex||1.19 (0.78–1.80)||0.43||1.45 (0.76–2.77)||0.26||1.64 (0.86–3.13)||0.13|
|Type of sleep study (PSG)||0.92 (0.61–1.36)||0.67||0.75 (0.36–1.54)||0.43||1.25 (0.61–2.59)||0.55|
|Sleep clinic||1.25 (0.85–1.87)||0.26||1.54 (0.83–2.86)||0.17||1.64 (0.87–3.01)||0.13|
|BMI||1.03 (0.99–1.07)||0.06||1.03 (0.99–1.07)||0.06||1.04 (0.99–1.07)||0.06|
|Smoked (≥30 pack-years)||1.37 (0.92–2.02)||0.12||1.67 (0.99–2.81)||0.05||1.53 (0.92–2.56)||0.11|
|ESS||1.02 (0.98–1.06)||0.29||1.04 (0.99–1.09)||0.10||1.03 (0.99–1.08)||0.13|
|Dyslipidemia||1.29 (0.86–1.90)||0.22||1.22 (0.81–1.83)||0.34||0.83 (0.55–1.25)||0.37|
|Diabetes mellitus||2.55 (1.71–3.79)||0.0001||2.54 (1.68–3.84)||0.0001||2.25 (1.47–3.43)||0.0001|
|Previous CVE||3.05 (2.04–4.55)||0.0001||—–||—––||2.22 (1.44–3.42)||0.0001|
|AHT||1.53 (0.94–2.48)||0.07||—–||—–||1.12 (0.68–1.85)||0.66|
|AHI < 15||1||1||1|
|AHI 15–29 without CPAP||1.98 (0.91–4.32)||0.09||1.62 (0.74–3.54)||0.23||1.38 (0.73–2.64)||0.32|
|OSA with CPAP||1.11 (0.57–2.16)||0.76||1.07 (0.53–2.17)||0.86||0.93 (0.46–1.89)||0.84|
|AHI ≥ 30 without CPAP||3.09 (1.57–6.10)||0.001||2.56 (1.24–5.29)||0.011||2.25 (1.41–3.61)||0.001|
Figure 3 shows that untreated severe OSA is associated with an increase in the risk of all-cause mortality (HR, 1.99; 95% CI, 1.42 to 2.81; P = 0.001), from stroke (HR, 4.63; 95% CI, 1.03 to 20.8; P = 0.046) and from heart failure (HR, 3.93; 95% CI, 1.13 to 13.65; P = 0.031), but there was no association with an increased risk of death from ischemic heart disease (HR, 1.09; 95% CI, 0.37 to 3.36; P = 0.23) compared with the control group.
CPAP treatment was associated with a reduced risk of all-cause and cardiovascular mortality, as well as death from stroke and heart failure, to levels similar to those of patients without OSA or with untreated, mild–moderate OSA (Figure 2 and Table 3). There were no changes, however, in the risk of death from ischemic heart disease (Figure 3). This association between untreated severe OSA and an increased risk of cardiovascular mortality (HR, 3.87; 95% CI, 1.12 to 13.3; P = 0.032) and the reduction of the risk with CPAP treatment (HR, 1.01; 95% CI, 0.27 to 3.36; P = 0.98) was also observed when we analyzed the subgroups of patients 75 years of age or older (n = 193; 37 deaths).
In those patients who started CPAP treatment (n = 698), compliance as a continuous variable was independently associated with a lower risk of cardiovascular mortality (HR, 0.48; 95% CI, 0.30 to 0.78; P = 0.003) (Table 4), whereas in untreated participants (n = 698), AHI as a continuous variable was independently associated with increased cardiovascular mortality (HR, 1.01; 95% CI, 1.00 to 1.02; P = 0.005) (Table 5).
|Fully Adjusted Model|
|Variable||HR (95% CI)||P Value|
|Body mass index||1.03 (0.99–1.08)||0.14|
|Previous CV events||2.08 (1.26–3.43)||0.004|
|Diabetes mellitus||2.66 (1.63–4.34)||<0.001|
|Smoked (≥30 pack-years)||1.90 (1.02–3.55)||0.04|
|CPAP adherence||0.48 (0.30–0.78)||0.003|
|Fully Adjusted Model|
|Variable||HR (95% CI)||P Value|
|Body mass index||1.02 (0.98–1.07)||0.34|
|Previous CV events||1.92 (1.08–3.4)||0.026|
|Diabetes mellitus||1.41 (0.80–2.46)||0.24|
|Smoked (≥30 pack-years)||0.96 (0.50–1.85)||0.91|
Finally, when the subgroups of patients were analyzed separately according to the type of diagnostic study used (RP [57% of patients] versus full PSG [43% of patients]), the results were similar to those obtained from the overall analysis of the entire group of patients. Thus, in the RP group the risk of cardiovascular death in those patients with severe untreated OSA was significantly higher than that of the control group (HR, 2.49; 95% CI, 1.15 to 5.39; P = 0.021), and this risk was normalized in those patients treated with CPAP (HR, 1.14; 95% CI, 0.66 to 1.98; P = 0.64). Similarly, a significantly greater risk of cardiovascular death was also observed in those patients with severe untreated OSA in the full PSG, compared with the control group (HR, 2.62; 95% CI, 1.12 to 9.67; P = 0.034), and this risk was normalized in those patients treated with CPAP (HR, 0.88; 95% CI, 0.18 to 4.3; P = 0.88). In the group with untreated mild–moderate OSA the risk was not significantly greater than that of the control group in either of the two subgroups of patients.
The main findings of this study were that, in elderly patients, severe OSA not treated with CPAP was associated with an increase in cardiovascular mortality due to stroke and heart failure, whereas treatment with CPAP was associated with a decrease in this excess of cardiovascular mortality to levels similar to those of patients without OSA.
Although there is little doubt that OSA is a risk factor for cardiovascular mortality, most studies to date have been performed on middle-aged men (4, 10, 17, 18), and there remains some controversy about its effect on the elderly population. Some studies have found a greater adjusted risk of cardiovascular morbidity and mortality in elderly patients with OSA, as reflected by an increase in night-time blood pressure (24), CVEs (25, 27), arrhythmias (26), and mortality (28, 29). Other authors, however, have concluded that OSA does not cause excess mortality in an elderly person, as opposed to a young one (16, 17). In this respect, Punjabi and colleagues (16), analyzing the subgroup of individuals aged over 70 years of both sexes in the population-based cohort of the Sleep Heart Health Study, did not observe any excess of all-cause mortality in relation to sleep-disordered breathing severity. Lavie and Lavie explained these paradoxical differences in the results between younger and elderly individuals via the “ischemic preconditioning” hypothesis, according to which long-term intermittent hypoxia in the elderly could trigger the formation of collateral neovascularization (19). This hypothesis has been confirmed by observing that patients with coronary occlusion and OSA presented a greater number of newly formed collaterals, which would theoretically protect them from death after a coronary event (20). According to this hypothesis, we found that severe untreated OSA was not associated with an increase in mortality from ischemic heart disease in elderly patients, compared with those who did not suffer from OSA. Our results are similar to those found in the analysis of the elderly cohort in the Sleep Heart Health Study, which also found that the incidence of coronary events did not increase in the subgroup of elderly people with OSA, in contrast with men less than 70 years of age (25). In any case, the number of deaths from ischemic heart disease observed in our study is low and so these results should be interpreted with caution.
In contrast, our study found an association between nontreated severe OSA and an increase in overall cardiovascular mortality in elderly people, as a consequence of an increase in deaths from stroke and heart failure. This concurs once again with the findings of two studies that analyzed the Sleep Heart Health Study cohort, which showed an increase in the incidence of new cardiovascular events caused by heart failure in the subgroup of elderly patients with OSA (25) or stroke (median age of patients with stroke, 72 yr) (27), although cardiovascular mortality was not analyzed in these studies. Although it could be supposed that the “ischemic preconditioning” hypothesis would endorse protection against intermittent hypoxia in any type of cardiovascular event, most of the data available on this compensatory mechanism derive from studies investigating its effect on coronary circulation (38–40), and the effect on cerebral circulation is much more open to debate, particularly in the case of elderly people (41–43). Thus, Wegener and colleagues reported that the protection provided against stroke development by an earlier period of cerebral ischemia (e.g., transient ischemic attack) does not depend on new vascular formation but rather on triggering intrinsic neuroprotective mechanisms unrelated to neovascularization (42).
Although an analysis of all-cause mortality was not our main objective, it is important to comment on the discrepancies observed between the results found by Punjabi and colleagues (16) in their analysis of the cohort from the Sleep Heart Health Study, where no excess of all-cause mortality was observed in individuals over 70 years of age with severe OSA, and the results of our study, in which an excess of mortality was found in elderly patients with untreated severe OSA. We believe that the explanation for this discrepancy lies in the different origins and characteristics of the series analyzed in the two studies. Whereas the study by Punjabi and colleagues (16) was population-based and therefore probably comprised a group of individuals with a low-risk cardiovascular risk profile and included a lower percentage of individuals with severe OSA, our study is clinically based and therefore includes a high percentage of patients with severe OSA (AHI ≥ 30; 62.6%) and a higher cardiovascular risk profile (38.5% of our patients had a previous history of cardiovascular events and 52.6% of the deaths were of cardiovascular origin).
To our knowledge, there is no study in the literature to date that analyzes the long-term impact of CPAP treatment on cardiovascular mortality in a large series consisting exclusively of elderly people. Marin and colleagues observed that CPAP provided protection against both fatal and nonfatal CVEs in middle-aged males (4), and Campos-Rodríguez and colleagues have reported similar results in women (44), although neither of these two studies analyzed elderly people separately (4). Our study shows, for the first time, that CPAP treatment in patients 65 years of age or older of both sexes (as well as in the subgroup ≥ 75 yr) normalizes the adjusted excess of general mortality (particularly of cardiovascular origin). This finding echoes the case of middle-aged men and could be explained by a reduction in deaths caused by cerebrovascular events and heart failure, without any changes in the mortality from coronary events.
The outstanding strengths of our study are the significant number of participants and the prolonged follow-up, making it possible to evaluate, for the first time, the impact of CPAP treatment in a wide-ranging series consisting exclusively of elderly people, with only a limited amount of missing data. Both participating hospitals were ideally situated, geographically, for this type of long-term study as their catchment areas are characterized by scarce movement of population and a single hospital for referrals. This meant that little information would have been lost. We used an AHI cutoff of 15 for the diagnosis of OSA (control group) in the elderly with clinical suspicion of OSA, as older individuals present an increase in the number of age-related respiratory events during sleep (12, 28, 29). In fact, less than 5% of our patients presented an AHI less than 5. The principal limitations of our study are as follows: first, the main limitation is that it does not feature any randomized intervention, but this would raise ethical issues in a prolonged study of this kind. Second, the statistical power is reduced in the analysis of the subgroups of patients 75 years of age or older and in the separate analysis of the different causes of cardiovascular death, so any change in this classification would provoke proportionally large changes in the event rates, meaning that these results must be interpreted with caution. The third limitation concerns the use of RP as a diagnostic method in a high percentage of patients. We wanted to carry out a real-life study that followed the practice of many countries, such as Spain, by using a diagnostic algorithm that would incorporate validated RP and PSG (32, 33). In any case, the error liable to be made by the use of RP is an underestimation of AHI through the use of the recording time (longer than the sleep time), which could lead to the classification of patients with severe OSA as mild–moderate. This means that if a full PSG had been used as a diagnostic method for all the patients the differences in cardiovascular mortality found between the groups not treated with CPAP and the other groups would probably have been greater; therefore, the use of RP does not undermine the conclusions of our study but, rather, reinforces them. Furthermore, all the RP devices used in the present study were correctly validated. Fourth, we have considered good compliance with CPAP to be a nightly use of at least 4 hours, measured by the device’s internal counter. The commonly accepted definition of good compliance includes not only this number of hours but also the use of the device for at least four nights per week (or 70% of nights) (45), but this information was not available for our study. In any case, we undertook a parallel analysis using compliance with CPAP, in number of hours of use per day, as a continuous variable, and the results were similar to those obtained by using the cutoff point of 4 hours/day to define good compliance. Finally, the causes of death were not verified by an autopsy, although every effort was made to check the veracity of the cause of death in all cases.
In conclusion, we have provided the first evidence that severe untreated OSA is associated with cardiovascular mortality in elderly people of both sexes. This excess of mortality seems to be the result of an increase in mortality from cerebrovascular and heart failure and CPAP treatment is associated with a decrease in the risk of mortality to levels similar to those found in patients without OSA. Although additional research is required, we believe this study is an important step in developing evidence for this common but relatively understudied disorder in the elderly.
|1.||Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1236.|
|2.||Barbé F, Pericás J, Muñoz A, Findley L, Antó JM, Agusti AG. Automobile accidents in patients with sleep apnea syndrome: an epidemiological and mechanistic study. Am J Respir Crit Care Med 1998;158:18–22.|
|3.||Terán-Santos J, Jiménez-Gómez A, Cordero-Guevara J; Cooperative Group Burgos-Santander. The association between sleep apnea and the risk of traffic accidents. N Engl J Med 1999;340:847–851.|
|4.||Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnea–hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046–1053.|
|5.||Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–1384.|
|6.||Sanders MH, Montserrat JM, Farré R, Givelber RJ. Positive pressure therapy: a perspective on evidence-based outcomes and methods of application. Proc Am Thorac Soc 2008;5:161–172.|
|7.||Durán-Cantolla J, Aizpuru F, Montserrat JM, Ballester E, Terán-Santos J, Aguirregomoscorta JI, González M, Lloberes P, Masa JF, de la Peña M, et al.. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnea: randomized controlled trial. BMJ 2010;341:c5991.|
|8.||Martínez-García MA, Soler-Cataluña JJ, Ejarque-Martínez L, Soriano Y, Román-Sánchez P, Barbé-Illa F, Montserrat JM, Durán-Cantolla J. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med 2009;180:36–41.|
|9.||Barbé F, Durán-Cantolla J, Capote F, de la Peña M, Chiner E, Masa JF, Gonzalez M, Marín JM, Garcia-Rio F, de Atauri JD, et al.. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010;181:718–726.|
|10.||Campos-Rodríguez F, Peña-Griñán N, Reyes-Nuñez N, de la Cruz-Morón I, Pérez-Ronchel J, de la Vega-Gallando F, Fernandez-Palacin A. Mortality in obstructive sleep apnea–hypopnea patients treated with positive airway pressure. Chest 2005;128:624–633.|
|11.||Duran J, Esnaola S, Rubio R. Prevalence of obstructive sleep apnea–hypopnea and related clinical features in the elderly: a population-based study in the general population aged 71–100. World Conference Sleep Odyssey, October 23–26, 2001. Punta del Este, Uruguay.|
|12.||Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: prevalence and severity. Am J Respir Crit Care Med 1998;157:144–148.|
|13.||Martínez-García MA, Amilibia J, Chiner E, Queipo C, Díaz de Atauri MJ, Carmona-Bernal C, Mayos M, García-Río F, Hernández Blasco L, Grau N, et al.. Apnea del sueño en individuos de edad avanzada: actividad asistencial (2002–2008). Arch Bronconeumol 2010;46:502–507.|
|14.||Marshall NS, Wong KKH, Liu PY, Cullen SRJ, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079–1085.|
|15.||Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, Stubbs R, Hla KM. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep Cohort. Sleep 2008;31:1071–1078.|
|16.||Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O’Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, et al.. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009;6:e1000132.|
|17.||Lavie P, Lavie L. Unexpected survival advantage in elderly people with moderate sleep apnea. J Sleep Res 2009;18:397–403.|
|18.||Lavie P, Lavie L, Herer P. All-cause mortality in males with sleep apnea syndrome: declining mortality rates with age. Eur Respir J 2005;27:1–7.|
|19.||Lavie L, Lavie P. Ischemic preconditioning as a possible explanation for the age decline relative to mortality in sleep apnea. Med Hypotheses 2006;66:1069–1073.|
|20.||Steiner S, Schueller PO, Schulze V, Strauer BE. Occurrence of coronary collateral vessels in patients with sleep apnea and total coronary occlusion. Chest 2010;137:516–520.|
|21.||Lavie L, Kraiczi H, Hefetz A, Ghandour H, Perelman A, Hedner J, Lavie P. Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment. Am J Respir Crit Care Med 2002;165:1624–1628.|
|22.||Muñoz R, Durán-Cantolla J, Martínez-Vila E, Gallego J, Rubio R, Aizpuru F, De La Torre G. Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke 2006;37:2317–2321.|
|23.||Martínez-García MA, Galiano-Blancart R, Román-Sánchez P, Soler-Cataluña JJ, Cabero-Salt L, Salcedo-Maiques E. Continuous positive airway pressure treatment in sleep apnea prevents new vascular events after ischemic stroke. Chest 2005;128:2123–2129.|
|24.||Endeshaw YW, White WB, Kutner M, Ouslander JG, Bliwise DL. Sleep-disordered breathing and 24-hour blood pressure pattern among older adults. J Gerontol A Biol Sci Med Sci 2009;64:280–285.|
|25.||Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al.. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010;122:352–360.|
|26.||Mehra R, Stone KL, Varosy PD, Hoffman AR, Marcus GM, Blackwell T, Ibrahim OA, Salem R, Redline S. Nocturnal arrhythmias across a spectrum of obstructive and central sleep-disordered breathing in older men: outcomes of sleep disorders in older men (MrOS sleep) study. Arch Intern Med 2009;169:1147–1155.|
|27.||Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O’Connor GT, Resnik HE, Diener-West M, Sanders MH, Wolf PA, Geraghty EM, et al.. Obstructive sleep apnea hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010;182:269–277.|
|28.||Ancoli-Israel S, Kripke DF, Klauber MF, Fell R, Stepnowsky C, Estline E, Khazeni N, Chinn A. Morbidity, mortality and sleep-disordered breathing in community dwelling elderly. Sleep 1996;19:277–282.|
|29.||Bliwise DL, Bliwise NG, Partinen M, Pursley MA, Dement WC. Sleep apnea and mortality in an aged cohort. Am J Public Health 1988;78:544–547.|
|30.||Martínez-García MA, Campos-Rodríguez F, Catalán-Serra F, de la Cruz-Morón I, Montserrat JM. All-cause and cardiovascular mortality in elderly patients with sleep apnea: role of CPAP treatment [abstract]. Am J Respir Crit Care Med 2011;183:A1058.|
|31.||Chiner E, Arriero J, Signes-Costa J, Marco J, Fuentes I. Validación de la versión Española del test de somnolencia Epworth en pacientes con síndrome de apnea de sueño. Arch Bronconeumol 1999;35:422–427.|
|32.||Sleep Spanish Group. Consenso Nacional sobre el Síndrome de apneas–hipopnoeas durante el sueño. Arch Bronconeumol 2005;41:30–80.|
|33.||Montserrat JM, Amilibia J, Barbe F, Capote F, Durán J, Mangado NG, Jiménez A, Marín JM, Masa F, Terán J. Tratamiento del síndrome de las apneas–hipopnoeas durante el sueño. Arch Bronconeumol 1998;34:204–206.|
|34.||Duran J, Esnaola S, Rubio R, Toña I, Egea C, Baquedano J. Estimación de la validez diagnóstica del sistema portátil Apnoscreen II en el diagnóstico del síndrome de apnea obstructiva durante el sueño. Arch Bronconeumol 1996;32:3.|
|35.||Gugger M. Comparison of ResMed AutoSet (version 3.03) with polysomnography in the diagnosis of the sleep apnea/hypopnea syndrome. Eur Respir J 1997;10:587–591.|
|36.||Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles: Brain Information Service/Brain Research Institute, University of California, Los Angeles, 1968.|
|37.||American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667–689.|
|38.||Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999;100:547–555.|
|39.||Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993;342:276–277.|
|40.||Lavie L, Lavie P. Coronary collateral circulation in sleep apnea: a cardioprotective mechanism? Chest 2010;137:511–512.|
|41.||Petcu EB, Smith RA, Miroiu RI, Opris MM. Angiogenesis in old-aged subjects after ischemic stroke: a cautionary note for investigators. J Angiogenes Res 2010;2:26.|
|42.||Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schelinger PD, Kucinski T, Jungehülsing GJ, Brunecker P, Müller B, et al.. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke 2004;35:616–621.|
|43.||Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008;8:754–767.|
|44.||Campos-Rodríguez F, Martínez-García MA, de la Cruz-Morón I, Almeida-González C, Catalán-Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea with and without continuous positive airway pressure treatment. Ann Intern Med 2012;156:115–122.|
|45.||Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008;5:173–178.|
Supported by public grants from the Sociedad Valenciana de Neumología (Valencian Pneumology Society) and from FIS (Fondo de Investigación Sanitaria) PI 11/01892, Instituto de Salud Carlos III.
Author Contributions: M.-A.M.-G. designed the study, contributed to data acquisition and interpretation, supervised the study, and wrote the manuscript. F.C.-R. designed the study, contributed to data acquisition and interpretation, and approved the final version to be published. P.C.-S. contributed to data acquisition and interpretation, critically revised the manuscript, and approved the final version to be published. J.-J.S.-C. performed statistical analyses and contributed to data interpretation, critically revised the manuscript, and approved the final version to be published. C.A.-G. and I.D.l.C.M. contributed to data acquisition and interpretation, critically revised the manuscript, and approved the final version to be published. J.D.-C. contributed to data acquisition and interpretation, critically revised the manuscript, and approved the final version to be published. J.-M.M. assisted in data interpretation, critically revised the manuscript, and approved the final version to be published. The corresponding author (M.-A.M.-G.) confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication. All the authors have approved this final draft.
Originally Published in Press as DOI: 10.1164/rccm.201203-0448OC on September 13, 2012